These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 37734750)

  • 1. Omalizumab for Chinese patients with moderate-to-severe allergic asthma in real-world clinical setting: a prospective, observational study.
    Wang W; Li J; Zou C; Zhao L; Zhu Y; Guo Y; Wang F
    BMJ Open Respir Res; 2023 Sep; 10(1):. PubMed ID: 37734750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of omalizumab in patients with severe allergic asthma: A retrospective study in China.
    Zhang M; Jin M; Zhou X; Lin J; Liu X; Liu C; Huang M; Wang W; Chen L; Huang Y; Li J; Zhang Q; Shen H; Yu Y; Tang W; Zhou J; Liu H; Dong L; Hu Y; Wu H; Li Y; Song W; Ouyang M; Yuan X; Wang T; Xiong S
    Respir Med; 2021 Sep; 186():106522. PubMed ID: 34229289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effectiveness and safety of omalizumab in severe, persistent IgE-mediated asthma in pediatric and adult patients: a real-world observational study in Egyptian population.
    Tarraf HN; Masoud HH; Zidan M; Wahba B
    J Asthma; 2020 Feb; 57(2):160-166. PubMed ID: 30592242
    [No Abstract]   [Full Text] [Related]  

  • 4. Add-on omalizumab in children with severe allergic asthma: a 1-year real life survey.
    Deschildre A; Marguet C; Salleron J; Pin I; Rittié JL; Derelle J; Taam RA; Fayon M; Brouard J; Dubus JC; Siret D; Weiss L; Pouessel G; Beghin L; Just J
    Eur Respir J; 2013 Nov; 42(5):1224-33. PubMed ID: 23520319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of omalizumab on treatment of severe allergic asthma in UK clinical practice: a UK multicentre observational study (the APEX II study).
    Niven RM; Saralaya D; Chaudhuri R; Masoli M; Clifton I; Mansur AH; Hacking V; McLain-Smith S; Menzies-Gow A
    BMJ Open; 2016 Aug; 6(8):e011857. PubMed ID: 27507234
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The real-life clinical effects of 52 weeks of omalizumab therapy for severe persistent allergic asthma.
    Gouder C; West LM; Montefort S
    Int J Clin Pharm; 2015 Feb; 37(1):36-43. PubMed ID: 25394832
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
    Tzortzaki EG; Georgiou A; Kampas D; Lemessios M; Markatos M; Adamidi T; Samara K; Skoula G; Damianaki A; Schiza S; Tzanakis N; Siafakas NM
    Pulm Pharmacol Ther; 2012 Feb; 25(1):77-82. PubMed ID: 22155001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma.
    Grossman HL; Schlender A; Alperin P; Stanley EL; Zhang J
    Curr Med Res Opin; 2010 Dec; 26(12):2779-93. PubMed ID: 21050061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.
    Casale TB; Luskin AT; Busse W; Zeiger RS; Trzaskoma B; Yang M; Griffin NM; Chipps BE
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):156-164.e1. PubMed ID: 29800752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of omalizumab in patients with inadequately controlled severe persistent allergic asthma: an open-label study.
    Niven R; Chung KF; Panahloo Z; Blogg M; Ayre G
    Respir Med; 2008 Oct; 102(10):1371-8. PubMed ID: 18657960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies.
    Bousquet J; Humbert M; Gibson PG; Kostikas K; Jaumont X; Pfister P; Nissen F
    J Allergy Clin Immunol Pract; 2021 Jul; 9(7):2702-2714. PubMed ID: 33486142
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Preliminary clinical observation of omalizumab therapy for moderate to severe asthma].
    Wu PH; Dong C; Xie JX; Zhang XX; Liu J; Ouyang M; Ma JJ; Huang WH; Ou CX; Li J; Zhang QL
    Zhonghua Jie He He Hu Xi Za Zhi; 2021 Jul; 44(7):611-618. PubMed ID: 34256447
    [No Abstract]   [Full Text] [Related]  

  • 14. Omalizumab for the treatment of severe persistent allergic asthma in children aged 6-11 years: a NICE single technology appraisal.
    Burch J; Griffin S; McKenna C; Walker S; Paton J; Wright K; Woolacott N
    Pharmacoeconomics; 2012 Nov; 30(11):991-1004. PubMed ID: 22950547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of omalizumab as add-on therapy on asthma-related quality of life in severe allergic asthma: a Brazilian study (QUALITX).
    Rubin AS; Souza-Machado A; Andradre-Lima M; Ferreira F; Honda A; Matozo TM;
    J Asthma; 2012 Apr; 49(3):288-93. PubMed ID: 22356355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world safety and efficacy of omalizumab in patients with severe allergic asthma: A long-term post-marketing study in Japan.
    Adachi M; Kozawa M; Yoshisue H; Lee Milligan K; Nagasaki M; Sasajima T; Miyamoto T; Ohta K
    Respir Med; 2018 Aug; 141():56-63. PubMed ID: 30053973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of omalizumab in cat-allergic patients with moderate-to-severe persistent asthma.
    Massanari M; Kianifard F; Zeldin RK; Geba GP
    Allergy Asthma Proc; 2009; 30(5):534-9. PubMed ID: 19467177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
    Solèr M; Matz J; Townley R; Buhl R; O'Brien J; Fox H; Thirlwell J; Gupta N; Della Cioppa G
    Eur Respir J; 2001 Aug; 18(2):254-61. PubMed ID: 11529281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term efficacy and safety of omalizumab in patients with allergic asthma: A real-life study.
    Papaioannou AI; Mplizou M; Porpodis K; Fouka E; Zervas E; Samitas K; Markatos M; Bakakos P; Papiris S; Gaga M; Papakosta D; Loukides S
    Allergy Asthma Proc; 2021 May; 42(3):235-242. PubMed ID: 33980337
    [No Abstract]   [Full Text] [Related]  

  • 20. Randomized Comparative Clinical Study of First Global Omalizumab Biosimilar with Innovator Product in Moderate to Severe Persistent Asthma.
    Apsangikar P; Ghadge P; Naik M; Nair S
    J Assoc Physicians India; 2020 Dec; 68(12):61-65. PubMed ID: 33247645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.